Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 57000 shares. The stock had previously closed at C$0.10.
Kane Biotech Trading Down 5.3 %
The company has a fifty day moving average of C$0.10 and a two-hundred day moving average of C$0.12. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42. The stock has a market capitalization of C$12.97 million, a price-to-earnings ratio of 2.25 and a beta of 0.52.
Insider Activity
In other news, Director Marc Edwards acquired 2,000,000 shares of Kane Biotech stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average price of C$0.10 per share, for a total transaction of C$200,000.00. Insiders own 37.21% of the company’s stock.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
See Also
- Five stocks we like better than Kane Biotech
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- How to Protect Your Portfolio When Inflation Is Rising
- Comparing and Trading High PE Ratio Stocks
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Manufacturing Stocks Investing
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
